Scientific Publications

Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response

Given that objective responses in 30% to 50% of patients suffering from metastatic melanoma is mediated by adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL), as per multiple, small phase 2 trials, so, researchers assessed long-term clinical outcomes, intent-to-treat analysis, predictors of response as well as toxicity profile in a large patient cohort.

Read More

Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo : A secondary analysis of a randomized clinical trial

In the present study, the researchers sought to explore the connection between immune-related adverse events and recurrence-free survival (RFS) in the double-blind EORTC 1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the treatment of individuals with high-risk stage III melanoma.

Read More
MRV News
Melanoma News
Archive
Menu